Abstract 7668: Novel pretreatment nomograms based on pan-Immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma

Abstract

Abstract Background: The prognostic value of an effective biomarker, Pan-Immune-Inflammation Value (PIV), for head and neck squamous cell carcinoma (HNSCC) patients after radical surgery or chemoradiotherapy has not been well explored. This study aimed to construct and validate nomograms based on PIV to predict survival outcomes of HNSCC patients. Methods: 161 HNSCC patients underwent radical surgery and 50 patients received chemoradiotherapy were enrolled retrospectively for development and external validation cohort, respectively. The cut-off of PIV was determined using the maximally selected rank statistics method. Multivariable Cox regression and least absolute shrinkage and selection operator (LASSO) regression analyses were performed to develop two nomograms (Model A and Model B) that predict disease-free survival (DFS). Results: Patients with higher PIV (≥123.3) experienced a worse DFS (HR: 5.01, 95% CI: 3.25-7.72, p<0.0001) and overall survival (OS) (HR: 5.23, 95% CI: 3.34-8.18, p<0.0001) compared to patients with lower PIV (<123.3), which was also consistent in the external cohort. Predictors of Model A included age, TNM stage, neutrophil-to-lymphocyte ratio (NLR) and PIV, and that of Model B included TNM stage, lymphocyte-to-monocyte ratio (LMR) and PIV. In comparison with TNM stage alone, the concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves of the nomograms demonstrated good calibration and discrimination, and the decision curve analysis (DCA) also showed satisfactory clinical utility in both internal and external validation. Conclusions: The nomograms based on PIV, a simple but forceful indicator, can provide intuitive and precise prognosis prediction of individual HNSCC patients after radical surgery or chemoradiotherapy. Citation Format: Qian Chen, Xiang Li, Yanxia Bai, Yue Chen. Novel pretreatment nomograms based on pan-Immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7668.